Investors & Media

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease

Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis Ionis to receive a $60 million upfront payment CARLSBAD, Calif. , Sept. 27, 2023 /PRNewswire/ — Ionis Pharmaceuticals , Inc.

Read more
You are now leaving to visit